Moroccan manufacturer IM MEDICARE officially opened a new $8.7 million production facility for hypodermic and vaccination syringes in Safi-Marrakech on January 16,2026,signaling a push for greater self-sufficiency in the nation’s medical device sector.The expansion,attended by Morocco’s Minister of Industry and Commerce,ryad Mezzour,will considerably increase the company’s capacity to 450 million syringes annually and create 70 jobs in the region[[2]]. IM MEDICARE’s recent World Health Association prequalification for its auto-disable syringe positions it as a key player in meeting growing demand for medical supplies both domestically and across Africa[[3]].
Moroccan medical device manufacturer IM MEDICARE inaugurated a new production facility dedicated to hypodermic and vaccination syringes on January 16, 2026, at the Sidi Bou Othmane industrial park in the Safi–Marrakech region. The opening was attended by Morocco’s Minister of Industry and Commerce, Ryad Mezzour.
The company is investing 85 million Moroccan dirhams (approximately $8.7 million USD) in the new unit, which is expected to create 70 direct jobs and boost IM MEDICARE’s annual production capacity to 450 million syringes. The increased output will serve both the domestic market and support Morocco’s growing export ambitions in Africa, a region with increasing demand for medical supplies.
The project directly addresses a national priority of strengthening Morocco’s self-sufficiency in the medical device sector. It also aims to contribute to the socio-economic development of the Safi–Marrakech region by creating skilled employment opportunities and bolstering the role of local businesses within the regional industrial landscape.
“This project illustrates the ability of Moroccan companies to innovate, produce with excellence, and establish themselves as reliable and recognized suppliers in the global vaccine device market,” Minister Mezzour stated at the opening ceremony. “It symbolizes the culmination of an ambitious vision to position Morocco in strategic sectors with high added value, contributing to the development of Made in Morocco, competitive import substitution, and the consolidation of our country’s health sovereignty.”
The Moroccan medical device industry has experienced significant growth in recent years, with the sector currently supporting 1,378 jobs, 376 million dirhams in investment, 903 million dirhams in revenue, and a value-added rate of 46%. This represents a rapid expansion of investment, activity, and wealth creation over the past twenty-five years.
A propos de IM MEDICARE :
IM MEDICARE was founded during the COVID-19 pandemic and, in 2025, received World Health Organization (WHO) prequalification for its 0.5 ml “Early Activation” auto-disable syringe. This recognition places the company among global manufacturers of vaccination devices that meet international standards for safety and quality. The certification allows IM MEDICARE to participate in international tenders, particularly those led by organizations involved in vaccination programs.
